Obesity is associated with poorer executive functioning and reward sensitivity. Yet, we know very little about whether weight loss through diet and/or increased exercise engagement improves cognitive function. This study evaluated whether weight loss following a dietary and exercise intervention was associated with improved cognitive performance. We enrolled 125 middle-aged adults with overweight and obesity (98 female) into a 12-month behavioral weight loss intervention. Participants were assigned to one of three groups: energy-restricted diet alone, an energy-restricted diet plus 150 min of moderate intensity exercise per week or an energy restricted diet plus 250 min of exercise per week. All participants completed tests measuring executive functioning and/or reward sensitivity, including the Iowa Gambling Task (IGT). Following the intervention, weight significantly decreased in all groups. A MANCOVA controlling for age, sex and race revealed a significant multivariate effect of group on cognitive changes. Post-hoc ANCOVAs revealed a Group × Time interaction only on IGT reward sensitivity, such that the high exercise group improved their performance relative to the other two intervention groups. Post-hoc ANCOVAs also revealed a main effect of Time, independent of intervention group, on IGT net payoff score. Changes in weight were not associated with other changes in cognitive performance. Engaging in a high amount of exercise improved reward sensitivity above and beyond weight loss alone. This suggests that there is additional benefit to adding exercise into behavioral weight loss regimens on executive functioning, even without additional benefit to weight loss.
Quadratic Discriminant Analysis (QDA) is a well-known and flexible classification method that considers differences between groups based on both mean and covariance structures. However, the connection structures of high-dimensional predictors are usually not explicitly incorporated into modeling. In this work, we propose a local network-guided QDA method that integrates the local connection structures of high-dimensional predictors. In the context of gene expression research, our method can identify genes that show differential expression levels as well as gene networks that exhibit different connection patterns between various biological state groups, thereby enhancing our understanding of underlying biological mechanisms. Extensive simulations and real data applications demonstrate its superior performance in both feature selection and outcome classification compared to commonly used discriminant analysis methods.
In November 2025, the U.S. FDA granted traditional approval to epcoritamab-bysp in combination with lenalidomide and rituximab (R2) for adults with relapsed or refractory (R/R) follicular lymphoma (FL). Approval was based on EPCORE FL-1, a randomized, open-label trial evaluating fixed durations of epcoritamab in combination with R2 compared with R2 alone in patients with R/R FL. Efficacy was based on the dual primary endpoints of progression-free survival (PFS) and overall response rate (ORR), as assessed by an independent review committee (IRC). By intention-to-treat analysis (N = 488), PFS was statistically significantly longer in the epcoritamab plus R2 arm, with a hazard ratio of 0.21 [95% confidence interval (CI), 0.13–0.33] and P < 0.0001 on the first interim analysis. The median PFS was not reached [95% CI, 22–not reached (NR)] in the epcoritamab plus R2 arm and was 11.2 months (95% CI, 10.5–NR) in the R2 arm. The ORR per IRC was significantly higher in the epcoritamab plus R2 arm, based on a prespecified analysis of the first 232 patients assessed (96% vs. 81% with R2; P < 0.0001). This article summarizes key aspects of the regulatory review, including endpoint selection, randomized dose optimization, and a potential single-trial approach to support both accelerated and subsequent traditional approval.